Journal of Hepatology
Volume 52, Issue 4 , Pages 493-500 , April 2010

Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues

  • Jurriën G.P. Reijnders

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    • ,
  • Katja Deterding

      Affiliations

    • Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany
    • ,
  • Jörg Petersen

      Affiliations

    • Department of Medicine, University of Hamburg, Hamburg, Germany
    • ,
  • Fabien Zoulim

      Affiliations

    • Department of Hepatology, Hotel Dieu Hospital Lyon, Lyon, France
    • ,
  • Teresa Santantonio

      Affiliations

    • Clinic of Infectious Diseases, University of Foggia, Foggia, Italy
    • ,
  • Maria Buti

      Affiliations

    • Department of Hepatology, Hospital Vall de Hebron, and Ciber-EHD, Barcelona, Spain
    • ,
  • Florian van Bömmel

      Affiliations

    • Department of Gastroenterology and Hepatology, Charité University Medical Center Berlin, Berlin, Germany
    • ,
  • Bettina E. Hansen

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    • ,
  • Heiner Wedemeyer

      Affiliations

    • Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Hannover, Germany
    • ,
  • Harry L.A. Janssen

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Gravendijkwal 230, Room Ha 204, 3015 CE Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 (0) 10 703 5942; fax: +31 (0) 10 436 5916.
    • ,
  • for the VIRGIL Surveillance Study Group

Received 8 June 2009 ,Revised 31 August 2009 ,Accepted 5 October 2009.

References 

  1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  2. Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother. 1998;42:3200–3208
  3. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
  4. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020
  5. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5years of therapy. Hepatology. 2009;49:1503–1514
  6. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96weeks. Hepatology. 2008;48:99–108
  7. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039–2049
  8. Tenney DJ, Pokornowski K, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at fiveyears shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int. 2008;2:S302–S303
  9. Christensen E. Multivariate survival analysis using Cox’s regression model. Hepatology. 1987;7:1346–1358
  10. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007;47:366–372
  11. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283–290
  12. Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24weeks. J Viral Hepat. 2009;16:113–120
  13. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41:1391–1398
  14. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12:355–362
  15. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003;39:1085–1089
  16. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48:747–755
  17. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131:1253–1261
  18. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol. 2009;50:674–683
  19. Rodriguez-Frias F, Jardi R, Schaper M, Gimferrer M, Elefsiniotis I, Tabernero D, et al. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues. J Med Virol. 2007;79:1671–1673
  20. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51:902–911
  21. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46:531–538
  22. Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol. 2008;48:895–902
  23. Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, et al. In vitro activity of 2, 4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother. 2007;51:2240–2243

PII: S0168-8278(10)00020-6

doi: 10.1016/j.jhep.2010.01.012

Journal of Hepatology
Volume 52, Issue 4 , Pages 493-500 , April 2010

Article Tools

* Image Usage & Resolution